<DOC>
	<DOC>NCT00264004</DOC>
	<brief_summary>The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.</brief_summary>
	<brief_title>Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Histological or cytological confirmation of advanced solid tumour, which is refractory to standard therapies or for which no standard therapy exists and for which there is a rationale for the therapeutic use of a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. Prior treatment with a VEGF inhibitor Poorly controlled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Advanced Solid Tumours</keyword>
	<keyword>phase II</keyword>
	<keyword>Hypertension</keyword>
	<keyword>RECENTIN</keyword>
</DOC>